Reports Q3 revenue $133.0M, consensus $130.5M. “Mirum is well positioned heading into 2026 with strong commercial momentum and multiple upcoming catalysts,” said Chris Peetz, Chief Executive Officer of Mirum. “Our third quarter results once again underscore the strength of our commercial medicines with continued strong performance. We also made important progress across the pipeline, including completing enrollment in the VISTAS PSC study, maintaining momentum in VANTAGE and EXPAND, and initiating our Phase 2 study in Fragile X Syndrome.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- MIRM Upcoming Earnings Report: What to Expect?
- Mirum Pharmaceuticals Advances in Fragile X Syndrome Treatment Study
- Mirum Pharmaceuticals’ Volixibat Study: A Potential Breakthrough for PBC Itching
- Mirum Pharmaceuticals Advances Phase 3 Study on Maralixibat for Cholestatic Pruritus
- Mirum Pharmaceuticals’ LEAP-US Study: A Long-Term Look at Livmarli’s Impact